RA0442

antibody from Oursmab
Targeting: KIR2DL3 CD158B2, cl-6, nkat2, nkat2a, nkat2b, p58
Provider product page for RA0442

Antibody data

Product number
RA0442 - Provider product page
Provider
Oursmab
Product name
Lirilumab (Biosimilar Reference Antibody) (KIRD2)
Antibody type
Monoclonal
Description
Lirilumab (also known as IPH-2102/BMS-986015) is a fully human monoclonal antibody that functions as an antagonist of killer cell immunoglobulin-like receptors (KIRs), specifically targeting the inhibitory receptors KIR2DL-1, -2, and -3 on natural killer (NK) cells and some T-cell subsets. By blocking these inhibitory KIRs, lirilumab prevents their interaction with their ligands (specific HLA-C allotypes) on tumor cells, thereby releasing the ¡°brake¡± on NK cell activity. This aims to enhance NK cell-mediated killing of tumor cells, a mechanism known as ¡°missing-self¡± recognition. It has been investigated clinically as an immuno-oncology agent, primarily in hematologic malignancies such as acute myeloid leukemia (AML) and multiple myeloma, often in combination with other therapies.
Reactivity
Human
Isotype
IgG
Vial size
100 ¦Ìg,1 mg,5 mg-500,10 mg,25 mg,50 mg,213 mg
Concentration
Bottled at the concentration indicated on the vial.
Storage
Store at -20¡ãC or -83¡ãC. Avoid repeated freeze.
KIR2DL3 protein structure - RA0442 shown in red.